These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21925549)

  • 21. Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression.
    Marek K; Jennings D; Tamagnan G; Seibyl J
    Ann Neurol; 2008 Dec; 64 Suppl 2():S111-21. PubMed ID: 19127587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biomarkers for trials of neuroprotection in Parkinson's disease.
    Agarwal PA; Stoessl AJ
    Mov Disord; 2013 Jan; 28(1):71-85. PubMed ID: 22927101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disease-modifying drugs and Parkinson's disease.
    Allain H; Bentué-Ferrer D; Akwa Y
    Prog Neurobiol; 2008 Jan; 84(1):25-39. PubMed ID: 18037225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peripheral Biomarkers for Early Detection of Alzheimer's and Parkinson's Diseases.
    Htike TT; Mishra S; Kumar S; Padmanabhan P; Gulyás B
    Mol Neurobiol; 2019 Mar; 56(3):2256-2277. PubMed ID: 30008073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson's disease.
    Bloem BR; Marks WJ; Silva de Lima AL; Kuijf ML; van Laar T; Jacobs BPF; Verbeek MM; Helmich RC; van de Warrenburg BP; Evers LJW; intHout J; van de Zande T; Snyder TM; Kapur R; Meinders MJ
    BMC Neurol; 2019 Jul; 19(1):160. PubMed ID: 31315608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarkers for the diagnosis and management of Parkinson's disease.
    Waragai M; Sekiyama K; Fujita M; Tokuda T; Hashimoto M
    Expert Opin Med Diagn; 2013 Jan; 7(1):71-83. PubMed ID: 23530844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Designing neuroprotection trials in Parkinson's disease.
    Kieburtz K
    Ann Neurol; 2003; 53 Suppl 3():S100-7; discussion S107-9. PubMed ID: 12666102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cerebrospinal fluid biomarkers for the early diagnosis of Parkinson's disease].
    da Costa AG; Gago MF; Garrett C
    Acta Med Port; 2011 Dec; 24 Suppl 4():761-8. PubMed ID: 22863482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proteomics Approach to Identify Biomarkers in Neurodegenerative Diseases.
    Nayak A; Salt G; Verma SK; Kishore U
    Int Rev Neurobiol; 2015; 121():59-86. PubMed ID: 26315762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative expression proteomics and phosphoproteomics profile of brain from PINK1 knockout mice: insights into mechanisms of familial Parkinson's disease.
    Triplett JC; Zhang Z; Sultana R; Cai J; Klein JB; Büeler H; Butterfield DA
    J Neurochem; 2015 Jun; 133(5):750-65. PubMed ID: 25626353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An update on the rotenone models of Parkinson's disease: their ability to reproduce the features of clinical disease and model gene-environment interactions.
    Johnson ME; Bobrovskaya L
    Neurotoxicology; 2015 Jan; 46():101-16. PubMed ID: 25514659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Unbiased Search of Biomarkers in Neurodegenerative Diseases.
    Ferrara P
    Curr Pharm Biotechnol; 2016; 17(5):471-9. PubMed ID: 26956112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomarkers in Huntington's and Parkinson's Disease.
    O'Keeffe GC; Michell AW; Barker RA
    Ann N Y Acad Sci; 2009 Oct; 1180():97-110. PubMed ID: 19906264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment.
    Svenningsson P; Westman E; Ballard C; Aarsland D
    Lancet Neurol; 2012 Aug; 11(8):697-707. PubMed ID: 22814541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomarkers in Parkinson's disease: an update.
    Shtilbans A; Henchcliffe C
    Curr Opin Neurol; 2012 Aug; 25(4):460-5. PubMed ID: 22772875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modelling of Parkinson's disease in mice.
    Chesselet MF; Richter F
    Lancet Neurol; 2011 Dec; 10(12):1108-18. PubMed ID: 22094131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are growth factors the answer?
    Ramaswamy S; Kordower JH
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S176-80. PubMed ID: 20082985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Molecular mechanisms of levodopa action in animal models of Parkinson's disease].
    Nowak P; Szczerbak G; Dabrowska J; Bortel A; Biedka I; Kostrzewa RM
    Neurol Neurochir Pol; 2006; 40(6):517-25. PubMed ID: 17199178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using mass spectrometry-based peptidomics to understand the brain and disorders such as Parkinson's disease and schizophrenia.
    Cafe-Mendes CC; Ferro ES; Britto LR; Martins-de-Souza D
    Curr Top Med Chem; 2014; 14(3):369-81. PubMed ID: 24304314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New concepts in the early and preclinical detection of Parkinson's disease: therapeutic implications.
    Akhtar RS; Stern MB
    Expert Rev Neurother; 2012 Dec; 12(12):1429-38. PubMed ID: 23237350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.